Dr Fallon on Guidelines for the Administration of Infection Prophylaxis in R/R Multiple Myeloma
May 24th 2023Michael J. Fallon, MD, discusses guidelines for the use and administration of infection prophylaxis in relapsed/refractory multiple myeloma, as well as the future role of prophylactic immunization in this landscape.
Risk- and Response-Adaptive Strategies Illuminate New Directions for Multiple Myeloma
February 9th 2022Although cytogenetic abnormalities have helped to characterize prognosis and identify patients who are at high risk of early progression, risk stratification has little effect on management decisions for most patients with multiple myeloma.
Sitravatinib, a spectrum-selective TKI targeting TAM receptors and VEGFR2, administered in combination with nivolumab induced durable response and robust survival outcomes for patients with non-small cell lung cancer who progressed after deriving benefit from treatment with a checkpoint inhibitor and/or platinum doublet chemotherapy.
Multiple Myeloma: Co-Chaired by Natalie S. Callander, MD and Parameswaran Hari, MD, MRCP
January 13th 2021Early detection, personalized treatment approaches, and increased situational awareness have improved cancer patient survival rates. Ongoing dialogue among leading experts can only improve patient outcomes and advance the field of multiple myeloma.